Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**

Published On: December 30, 2015 | Pages: 009 - 017

Author(s): Roberto Focaccia*, Rodolfo Ferreira de Mello, Patrícia Silva Montes and Flávio Martin Conti

Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated interferon and ribavirin (PR) is only recommended to patients with tolerance to interferon (IFN). IFN-free treatments are now considered elective drugs for patients with chronic HCV. More than 90% of patients infected with HCV ge ...

DOI: 10.17352/ahr.000003

Current Trends of Combination Therapy in Chronic Hepatitis B Management in China

Published On: August 28, 2015 | Pages: 001 - 004

Author(s): En-Qiang Chen*

In the past decade, five oral nucleos(t)ide analogs and two formulations of pegylated interferon alpha have been approved for the treatment of chronic hepatitis B (CHB). Due to low personal income and inadequate health care system, low-to-moderate genetic barrier antiviral drugs are still widely used in China, which brings increased suboptimal response, viral relapse ...

DOI: 10.17352/ahr.000001

Association of the Treatment Induced Clearance of Hepatitis C Virus Infection
Background: It has been shown that single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) gene were associated with sustained viral response following standard treatment of hepatitis C virus infection. Aim: The aim of the study was to evaluate the association between the SNPs near the IL28B gene and the response to the treatment of chronic hepatitis ...